Glucocorticoids are the mainstay of treatment for patients with polymyalgia rheumatica (PMR) and often produce substantial clinical improvements, but treatment can be complicated by relapse, adverse effects of therapies, and concomitant conditions. New recommendations aim to guide clinicians and improve the management of this disorder.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Dejaco, C. et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann. Rheum. Dis. 74, 1799–1807 (2015).
Dejaco, C. et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheumatol. 67, 2569–2580 (2015).
González-Gay, M. A., Garcia-Porrua, C., Salvarani, C., Olivieri, I. & Hunder, G. G. The spectrum of conditions mimicking polymyalgia rheumatica in Northwestern Spain. J. Rheumatol. 27, 2179–2184 (2000).
González-Gay, M. A. Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions. Semin. Arthritis Rheum. 33, 289–293 (2004).
González-Gay, M. A., Garcia-Porrua, C., Salvarani, C. & Hunder, G. G. Diagnostic approach in a patient presenting with polymyalgia. Clin. Exp. Rheumatol. 17, 276–278 (1999).
Salvarani, C., Cantini, F., Boiardi, L. & Hunder, G. G. Polymyalgia rheumatica and giant-cell arteritis. N. Engl J. Med. 347, 261–271 (2002).
Dejaco, C. et al. Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica. Ann. Rheum. Dis. 74, 1808–1817 (2015).
González-Gay, M. A. et al. The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study. J. Rheumatol. 26, 1326–1332 (1999).
Kremers, H. M. et al. Relapse in a population based cohort of patients with polymyalgia rheumatica. J. Rheumatol. 32, 65–73 (2005).
Mori, S. & Koga, Y. Glucocorticoid-resistant polymyalgia rheumatica: pretreatment characteristics and tocilizumab therapy. Clin. Rheumatol. http://dx.doi.org/10.1007/s10067-014-2650-y.
Acknowledgements
The work of M.A.G.-G. is supported by grants from Fondo de Investigaciones Sanitarias, Spain (PI06/0024, PS09/00748 and PI12/00060), and also partially supported by RETICS Program, RD08/0075 and RD12/0009/0013 (RIER) from Instituto de Salud Carlos III, Spain.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
González-Gay, M., Llorca, J. Best practices and uncertainties in the management of PMR. Nat Rev Rheumatol 12, 3–4 (2016). https://doi.org/10.1038/nrrheum.2015.142
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2015.142
